Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068 | Zendy

Nannan Zhou | Zendy; Beata Nowicka-Sans | Zendy; Brian McAuliffe | Zendy; Neelanjana Ray | Zendy; B. Eggers | Zendy; Hua Fang | Zendy; Fan Li | Zendy; Matthew D. Healy | Zendy; David R. Langley | Zendy; Carey Hwang | Zendy; Max Lataillade | Zendy; George J. Hanna | Zendy; Mark Krystal | Zendy

Open Access

Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068

Author(s) -

Nannan Zhou,

Beata Nowicka-Sans,

Brian McAuliffe,

Neelanjana Ray,

B. Eggers,

Hua Fang,

Fan Li,

Matthew D. Healy,

David R. Langley,

Carey Hwang,

Max Lataillade,

George J. Hanna,

Mark Krystal

Publication year - 2013

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkt412

Subject(s) - genotype , prodrug , virology , biology , virus , in vitro , drug resistance , genetics , pharmacology , gene

In an 8 day monotherapy study of subjects infected with HIV-1 (subtype B) (NCT01009814), BMS-626529 (an attachment inhibitor that binds to HIV-1 envelope glycoprotein gp120), administered as the prodrug BMS-663068, produced substantial declines in plasma HIV-1 RNA. However, large variability in susceptibility to BMS-626529 was noted and virus with low susceptibility was less likely to be suppressed by BMS-663068 administration. The current analysis sought to investigate the genotypic correlates of susceptibility to BMS-626529.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research